Current and future antiretroviral treatment options in paediatric HIV infection

Clinical Drug Investigation

Volumn 28, Issue 6, 2008, Pages 375-397

  Giaquinto, Carlo ^a   Morelli, Erika ^a   Fregonese, Federica ^a   Rampon, Osvalda ^a   Penazzato, Martina ^a   De Rossi, Anita ^a   D'Elia, Ruggero ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Antiretrovirals, therapeutic use; CCR5 receptor antagonists, therapeutic use; Children; Darunavir, therapeutic use; Efavirenz, therapeutic use; Elvitegravir, therapeutic use; Enfuvirtide, therapeutic use; Etravirine, therapeutic use

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; VIRUS RNA; ZIDOVUDINE;

CD4 LYMPHOCYTE COUNT; CHILD; CHILD CARE; DRUG APPROVAL; DRUG CHOICE; DRUG INDICATION; DRUG RESEARCH; DRUG TOLERABILITY; DYSLIPIDEMIA; FOOD AND DRUG ADMINISTRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIPODYSTROPHY; LIVER FAILURE; LIVER TOXICITY; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINASE INHIBITION; REVIEW; SKIN TOXICITY; TREATMENT PLANNING; VERTICAL TRANSMISSION; VIRUS LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; RNA, VIRAL; SALVAGE THERAPY;

EID: 43849110759     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200828060-00005     Document Type: Review

References (117)

1. World Health Organization (WHO). Antiretroviral treatment of HIV infection in infants and children in resource-limited settings, towards universal access: recommendations for a public health approach (2006 revision) [online]. Available from URL: http://www.who.int/hiv/pub/guidelines/art/en/ index.html [Accessed 2007 Jul 1]
2. de Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 2000; 284 (2): 190-7
3. Gibb DM, Duong T, Tookey PA, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ 2003; 327 (7422): 1019
4. World Health Organization (WHO). Progress on global access to HIV antiretroviral therapy: a report on "3 by 5" and beyond (March 2006) [online]. Available from URL: http://www.wpro.who.int/health_topics/ antiretroviral_therapy/publications.htm [Accessed 2007 Jul 1]
5. Doerholt K, Duong T, Tookey P, et al. Outcomes for human immunodeficiency virus-1-infected infants in the United kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Pediatr Infect Dis J 2006; 25 (5): 420-6
6. Amaya RA, Kozinetz CA, McMeans A, et al. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002; 21 (5): 405-10
7. Leonard EG, McComsey GA. Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J 2003; 22 (1): 77-84
8. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collabo- rative analysis of prospective studies. Lancet 2002; 360 (9327): 119-29
9. Florence E, Lundgren J, Dreezen C, et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med 2003; 4 (3): 255-62
10. Palella Jr FJ, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003; 138 (8): 620-6
11. Centers for Disease Control and Prevention. 1994 revised classi- fication system for human immunodeficiency infection in children less than 13 years of age. MMWR Recomm Rep 1994 Sep 30; 43 (RR-12): 1-19
12. Burns DN, Mofenson LM. Paediatric HIV-1 infection. Lancet 1999; 354 Suppl. 2: SII1-6
13. Dorrucci M, Rezza G, Porter K, et al. Temporal trends in postseroconversion CD4 cell count and HIV load: the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002. J Infect Dis 2007; 195 (4): 525-34
14. HIV Paediatric Prognostic Markers Collaborative Study. Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longi-tudinal data. Lancet 2005; 366 (9500): 1868-74
15. HIV Paediatric Prognostic Markers Collaborative Study. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS 2006; 20 (9): 1289-94
16. Dunn D. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003; 362 (9396): 1605-11
17. Sharland M, Blanche S, Castelli G, et al. PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med 2004; 5 Suppl. 2: 61-86
18. François-Xavier Bagnoud Center, UMDNJ, The Health Resources and Services Administration, et al. Working group on antiretroviral therapy and medical management of HIV-infected children: guidelines for the use of antiretroviral agents in pediatric HIV infection [online]. Available at URL: http://aidsinfo.nih.gov/contentfiles/PediatricGuidelines.pdf [Accessed 2008 Apr 30]
19. Italian guidelines for antiretroviral therapy in children with human immunodeficiency virus-type 1 infection. Italian Register for HIV Infection in Children. Acta Paediatr 1999; 88 (2): 228-32
20. Niehues T, Wintergerst U, Funk M, et al. Recommendations for antiretroviral therapy in HIV-infected children: completely revised and updated consensus statement of the Pediatric AIDS Committee (PAAD) and the German Society for Pediatric Infectiology. Monatsschr Kinderheilk 2001; 149: 1372-82
21. Borleffs JC, Danner SA, Lange JM, et al. Commissie Richtlijnen van de Nederlandse Vereniging van Aids Behandelaren. CBO guidelines Antiretroviral therapy in the Netherlands [in Dutch]. Ned Tijdschr Geneeskd 2001; 145 (33): 1585-9
22. Giaquinto C, Rampon O, Penazzato M, et al. Nucleoside and nucleotide reverse transcriptase inhibitors in children. Clin Drug Investig 2007; 27 (8): 509-31
23. Handforth J, Sharland M. Triple nucleoside reverse transcriptase inhibitor therapy in children. Paediatr Drugs 2004; 6 (3): 147-59
24. Pensieroso S, Romiti ML, Palma P, et al. Switching from protease inhibitor-based-HAART to a protease inhibitor-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children. AIDS 2006; 20 (14): 1893-6
25. Bartlett JA, Fath MJ, Demasi R, et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006; 20 (16): 2051-64
26. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354 (3): 251-60
27. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292 (2): 191-201
28. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med 1999; 341 (25): 1874-81
29. Bartlett JA, Johnson J, Herrera G, et al. Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir, or stavudine. J Acquir Immune Defic Syndr 2006; 43 (3): 284-92
30. DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004; 39 (7): 1038-46
31. Gulick RM, Ribaudo HJ, Shikuma CM, et al. ACTG 5095: zidovudine/ lamivudine/abacavir vs zidovudine/lamivudine + efavirenz vs zidovudine/ lamivudine/abacavir + efavirenz for initial HIV therapy. In: Antimicrobial Agents and Chemotherapy: 45th Interscience Conference, 2005, Washington, DC
32. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350 (18): 1850-61
33. Moyle GJ, DeJesus E, Cahn P, et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr 2005; 38 (4): 417-25
34. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349 (24): 2293-303
35. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349 (24): 2304-15
36. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults: study 006 team. N Engl J Med 1999; 341 (25): 1865-73
37. Tashima K, Staszewski S, Nelson M, et al. Durable viral suppression on EFV-based HAART: 168 weeks of follow-up [abstract no. TUPEB4547]. Presented at the 15th International AIDS Conference; 2004 Jul 11-16; Bangkok
38. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363 (9417): 1253-63
39. Carr A. Antiretroviral therapy for previously untreated HIV-1-infected adults: 2NN, or just one? Lancet 2004; 363 (9417): 1248-50
40. Manfredi R, Calza L, Chiodo F. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. J Acquir Immune Defic Syndr 2004; 35 (5): 492-502
41. Manosuthi W, Sungkanuparph S, Vibhagool A, et al. Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naive patients with advanced HIV infection. HIV Med 2004; 5 (2): 105-9
42. Teglas JP, Quartier P, Treluyer JM, et al. Tolerance of efavirenz in children. AIDS 2001; 15 (2): 241-3
43. Krogstad P, Lee S, Johnson G, et al. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. Clin Infect Dis 2002; 34 (7): 991-1001
44. Luzuriaga K, Bryson Y, Krogstad P, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997; 336 (19): 1343-9
45. Luzuriaga K, Bryson Y, McSherry G, et al. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis 1996; 174 (4): 713-21
46. Luzuriaga K, McManus M, Mofenson L, et al. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med 2004; 350 (24): 2471-80
47. Mirochnick M, Clarke DF, Dorenbaum A. Nevirapine: pharmacokinetic considerations in children and pregnant women. Clin Pharmacokinet 2000; 39 (4): 281-93
48. Verweel G, Sharland M, Lyall H, et al. Nevirapine use in HIV-1-infected children. AIDS 2003; 17 (11): 1639-47
49. Wiznia A, Stanley K, Krogstad P, et al. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial: PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team. AIDS Res Hum Retroviruses 2000; 16 (12): 1113-21
50. King JR, Nachman S, Yogev R, et al. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403. Pediatr Infect Dis J 2005; 24 (10): 880-5
51. Kiertiburanakul S, Khongnorasat S, Rattanasiri S, et al. Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients. J Med Assoc Thai 2007; 90 (2): 237-43
52. L'Homme RF, Dijkema T, Warris A, et al. Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults. J Antimicrob Chemother 2007; 59 (1): 92-6
53. Pujari SN, Patel AK, Naik E, et al. Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J Acquir Immune Defic Syndr 2004; 37 (5): 1566-9
54. Vezina HE, Henry K, Ravindran GD, et al. A randomized crossover study to determine bioequivalence of generic and brand name nevirapine, zidovudine, and lamivudine in HIV-negative women in India. J Acquir Immune Defic Syndr 2006; 41 (2): 131-6
55. Wamalwa DC, Farquhar C, Obimbo EM, et al. Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. J Acquir Immune Defic Syndr 2007; 45 (3): 311-7
56. Novak RM, Chen L, MacArthur RD, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 2005; 40 (3): 468-74
57. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004; 189 (12): 2174-80
58. Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192 (6): 958-66
59. Kontorinis N, Dieterich DT. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 2003; 23 (2): 173-82
60. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191 (6): 825-9
61. Shepard K. Clarification of risk factors for severe, life threatening and fatal hepatotoxicity with Viramune (nevirapine) [letter]. Rigdefield (CT): Boehringer Ingelheim Pharmaceuticals, 2004
62. Mocroft A, Staszewski S, Weber R, et al. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and - experienced HIV-infected patients with high and low CD4+ T-cell counts. Antivir Ther 2007; 12 (3): 325-33
63. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15 (15): 1951-7
64. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285 (16): 2083-93
65. Kaletra® (lopinavir-ritonavir tablets, oral solution). Prescribing information. North Chicago (IL): Abbott Laboratories, 2007
66. Pinto J, Robbins B, Chen J, et al. Pharmacokinetics and 24-week efficacy and safety of lopinavir/ritonavir in HIV-1 infected infants < 6 weeks of age. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25-28; Los Angeles (CA)
67. Murphy RL, da Silva B, McMillan F, et al. Seven-year followup of a lopinavir/ritonavir (LPV/r)-based regimen in antiretroviral (ARV)-naive subjects [poster PE7.9/3]. European AIDS, 10th Conference; 2005 Nov 17-20: Dublin
68. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346 (26): 2039-46
69. Gathe Jr JC, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004; 18 (11): 1529-37
70. Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2004; 35 (1): 22-32
71. Chadwick E, Borkowsky W, Fortuny C, et al. Safety and antiviral activity of fosamprenavir/ritonavir once daily regimens in HIV-infected pediatric subjects ages 2 to 18 years (48-week interim data, study APV20003) [abstract no. 719]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25-28; Los Angeles (CA))
72. Cunningham C, Freedman A, Read S, et al. Safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old pediatric subjects (interim data, study APV29005) [abstract no. 718]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25-28; Los Angeles (CA)
73. PREA Labeling Changes. Lexiva oral suspension (fosamprenavir) [online]. Available from URL: http://www.fda.gov/ cder/foi/label/2007/022116lbl.pdf [Accessed 2008 Apr 30]
74. Eron Jr JJ, Yeni GP, Gathe Jr JC, et al. The KLEAN study: fosamprenavir + ritonavir (FPV/r) versus lopinavir/ritonavir (LPV/r) in antiretroviral-naive (ART-naive) HIV-1 infected adults over 48 weeks. XVI International AIDS; 2006 Aug 13-18; Toronto
75. Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003; 17 (18): 2603-14
76. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36 (5): 1011-9
77. Malan N, Krantz E, David N, et al. Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5-8, Denver (CO)
78. Rutstein R, Samson P, Kiser J, et al. The PACTG 1020A protocol: atazanavir with or without ritonavir in HIV-infected infants, children, and adolescents. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25-28; Los Angeles (CA)
79. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006; 368 (9534): 466-75
80. Katlama C, Berger DS, Bellos N, et al. Efficacy of TMC114/r in 3-class experienced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding trials. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22-25, Boston (MA)
81. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services 2007; Washington, DC: 1-136
82. Bartlett JA, Johnson J, Herrera G, et al. Initial therapy with abacavir + lamivudine (ABC + 3TC) combined with efavirenz (NNRTI), amprenavir/ritonavir (PI), or stavudine (NRTI): ESS40001 (CLASS). In: International AIDS, 15th Conference; 2004: Bangkok
83. Riddler SA, Haubrich R, DiRienzo G, et al. A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection: ACTG 5142. IXVI International AIDS; 2006 Aug 13-18; Toronto
84. MacArthur RD, Novak RM, Peng G, et al. Long-term clinical and immunologic outcomes are similar in HIV-infected persons randomized to NNRTI vs PI vs NNRTI + PI-based antiretroviral regimens as initial therapy: results of the CPCRA 058 FIRST study. XVI International AIDS; 2006 Aug 13-18; Toronto
85. Resino S, Bellon JM, Munoz-Fernandez MA. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency. J Antimicrob Chemother 2006; 57 (3): 579-82
86. Resino S, Bellon JM, Ramos JT, et al. Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2004; 23 (10): 923-30
87. Resino S, Galan I, Perez A, et al. Immunological changes after highly active antiretroviral therapy with lopinavir-ritonavir in heavily pretreated HIV-infected children. AIDS Res Hum Retroviruses 2005; 21 (5): 398-406
88. Wiznia A, Church J, Emmanuel P, et al. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients. Pediatr Infect Dis J 2007; 26 (9): 799-805
89. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348 (22): 2175-85
90. Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus Optimized background Regimen Only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005; 40 (4): 404-12
91. Nadler JP, Berger DS, Blick G, et al. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. AIDS 2007; 21 (6): F1-10
92. Gazzard BG, Pozniak AL, Rosenbaum W, et al. An open-label assessment of TMC 125: a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 2003; 17 (18): F49-54
93. Gruzdev B, Rakhmanova A, Doubovskaya E, et al. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS 2003; 17 (17): 2487-94
94. Cohen C, Steinhart CR, Ward D, et al. Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virologic response in study TMC125, and impact of baseline resistance on the virologic response in study TMC125-C223. XVI International AIDS; 2006 Aug 13-18; Toronto
95. Schapiro JM, Cahn P, Trottier B, et al. Effect of baseline genotype on response to tipranavir/ritonavir compared with standard-of-care comparator in treatment-experienced patients: the phase 3 RESIST-1 and -2 trials. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22-25, Boston (MA)
96. Baxter JD, Schapiro JM, Boucher CA, et al. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 2006; 80 (21): 10794-801
97. Sabo JP, Cahn P, Della Negra M, et al. Population pharmacokinetic (PK) assessment of systemic steady-state tipranavir (TPV) concentrations for HIV + pediatric patients administered tipranavir/ritonavir (TPV/r 290/115 mg/m2 BID BI1192.14 and PACTG 1051 study team). 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5-8, Denver (CO)
98. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296 (7): 827-43
99. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369 (9568): 1169-78
100. Ananworanich J, Kosalaraksa P, Hill A, et al. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatr Infect Dis J 2005; 24 (10): 874-9
101. Calmy A, Petoumenos K, Lewden C, et al. Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts. HIV Med 2007; 8 (3): 171-80
102. Fischl MA, Collier AC, Mukherjee AL, et al. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen. AIDS 2007; 21 (3): 325-33
103. La Porte CJ, Wasmuth JC, Schneider K, et al. Lopinavir/ritovinar plus saquinavir in salvage therapy: pharmacokinetics, tolerability and efficacy. AIDS 2003; 17: 1700-2
104. Smith GH, Boulassel MR, Klien M, et al. Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients. HIV Clin Trials 2005; 6: 63-72
105. Temesgen Z, Cainelli F, Poeschla EM, et al. Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults. Lancet Infect Dis 2006; 6 (8): 496-507
106. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287 (5453): 646-50
107. Zolopa A, Mullen M, Berger DS, et al. The HIV integrase inhibitor GS-9137 demonstrates potent antiretroviral activity in treatment-experienced patients. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25-28; Los Angeles (CA)
108. Cooper D, Gatell J, Rockstroh J, et al. Results of BENCHMRK-1, a phase 111 study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25-28; Los Angeles (CA)
109. Steigbigel R, Kumar P, Eron Jr JJ, et al. Results of BENCHMRK-2, a phase 111 study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25-28; Los Angeles (CA)
110. Reeves JD, Piefer AJ. Emerging drug targets for antiretroviral therapy. Drugs 2005; 65 (13): 1747-66
111. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007; 81 (5): 2359-71
112. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49 (11): 4721-32
113. Fatkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005; 11 (11): 1170-2
114. Lalezari JP, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/3 study in the US and Canada. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25-28; Los Angeles (CA)
115. Nelson M, Fatkenheuer G, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25-28; Los Angeles (CA)
116. Hatano H, Deeks SG. Drug resistant HIV. BMJ 2007; 334 (7604): 1124-5
117. Regulation (EC) no 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No. 726/2004. Official Journal of the European Union [online]. Available from URL: http://eurlex.europa.eu/LexUriServ/ LexUriServ.do?uri=CONSLEG:2006R1901:20070126:EN: PDF [Accessed 2008 Apr 30]